SCHEMBL1828075

SCHEMBL1828075

CC(=O)NCC(C(=O)OC(C)(C)C)c1ccc(OS(=O)(=O)c2ccccc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPT P10636 1/20 0.41
RECQL P46063 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
ADAMTS4 O75173 1/20 0.40
MMP13 P45452 1/20 0.39
P2RX7 Q99572 8/20 0.39
TDP1 Q9NUW8 1/20 0.39
LMNA P02545 1/20 0.39
MTNR1A P48039 1/20 0.39
MTNR1B P49286 1/20 0.39
ENPP3 O14638 2/20 0.38
ENPP1 P22413 2/20 0.38
EGFR P00533 1/20 0.38
KDM4E B2RXH2 1/20 0.37
KDM4A O75164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1827842 0.91 EGFR (0.43) ALDH1A1SMN1; SMN2ADAMTS4MMP13P2RX7
SCHEMBL1826369 0.89 MTNR1A (0.45) ALDH1A1MEN1KMT2AMAPTRECQL
SCHEMBL1825655 0.89 MTNR1A (0.43) ALDH1A1SMN1; SMN2MMP13MTNR1AMTNR1B
SCHEMBL3570718 0.87 P2RX7 (0.49) MAPTP2RX7
SCHEMBL1824335 0.87 SMN1; SMN2 (0.44) ALDH1A1MEN1KMT2ASMN1; SMN2ADAMTS4
SCHEMBL1824701 0.86 EGFR (0.43) ALDH1A1SMN1; SMN2ADAMTS4MMP13P2RX7
SCHEMBL1822702 0.86 ADAMTS4 (0.43) ALDH1A1MEN1KMT2AMAPTRECQL
SCHEMBL1825277 0.85 MTNR1A (0.36) ALDH1A1MEN1KMT2AMAPTRECQL
SCHEMBL1824380 0.85 ATM (0.46) ALDH1A1KMT2ASMN1; SMN2ADAMTS4P2RX7
SCHEMBL1824569 0.85 CA1 (0.41) ALDH1A1SMN1; SMN2ADAMTS4MMP13P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2161254-B1 Intermediate for preparing a biaryl compound SUMITOMO CHEMICAL CO (JP) 2014-08-13 EP disclosed
EP-1481967-B1 PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS SUMITOMO CHEMICAL CO (JP) 2011-05-04 EP disclosed
US-7714157-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-05-11 US disclosed
EP-2161254-A1 Intermediate for preparing a biaryl compound Sumitomo Chemical Company, Limited (JP) 2010-03-10 EP disclosed
US-20070270603-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2007-11-22 US disclosed
US-7271280-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-18 US disclosed
EP-1481967-A1 PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS Sumitomo Chemical Company, Limited (JP) 2004-12-01 EP disclosed
US-20040158093-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040158093-A1 Process for preparing a biaryl compound CYP1B1, REL, CYP2F1 ALDH1A1 1099/4885MEN1 421/4885KMT2A 1068/4885
US-20070270603-A1 Process for preparing a biaryl compound CYP4A11, CYP4B1, CYP51A1 ALDH1A1 1440/4885MEN1 183/4885KMT2A 1084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.